
Lirilumab, Innate Pharma’s acute myeloid leukaemia (AML) treatment, has failed to meet its primary end point in a recent Phase …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

